Evidence map›Paper›PMID 40214726›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Nano-carrier, design, synthesis, in silico ADMET, anti-proliferative assessments and docking of [1,2,4]triazolo[4,3-a]quinoxalines as Topo-II inhibitors and DNA intercalators.

Ahmed K B Aljohani, Sara A Almadani, Marwa Alsulaimany, Naif Aljuhani, Waad A Samman, Adel H Al-Shareef, Read Alghamdi, Saeed M Tayeb, Hussam Y Alharbi, Majed S Aljohani and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Synthesis and Biological Activity of Azolo[Molecules (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ahmed K B AljohaniDepartment of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, 42353, Medina, Saudi Arabia.
Sara A AlmadaniDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, 42353, Medina, Saudi Arabia.
Marwa AlsulaimanyDepartment of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, 42353, Medina, Saudi Arabia.
Naif AljuhaniDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, 42353, Medina, Saudi Arabia.
Waad A SammanDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, 42353, Medina, Saudi Arabia.
Adel H Al-ShareefDepartment of Chemistry, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Read AlghamdiDepartment of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, 42353, Medina, Saudi Arabia.
Saeed M TayebDepartment of Pharmaceutical Science, College of Pharmacy, Umm Al-Qura University, 24381, Makkah, Saudi Arabia.
Hussam Y AlharbiDepartment of Chemistry, Faculty of Science, Taibah University, Yanbu, Saudi Arabia.
Majed S AljohaniDepartment of Chemistry, Faculty of Science, Taibah University, Yanbu, Saudi Arabia.
Khaled El-AdlPharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt. eladlkhaled74@azhar.edu.eg.
Mo'men SalemDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sinai University-Arish Branch, Arish, Egypt.

Funding

Umm Al-Qura University, Saudi Arabia 25UQU4350051GSSR01NI
6 · The paper itself

Abstract

Newly synthesized compounds 7, 8, and 9 and their nanogels as nano-carrier drug delivery systems have been synthesized and estimated for their cytotoxicity on MCF-7, HCT-116, HepG2, and A549. This research emphasizes on the formation and description of the Cs/PVA nanogel loaded with our derivatives 7, 8, and 9. The stability of nanogel formation was elucidated by zeta potential values which remained negative with values of -6.8, -11.8, and -7.8 mV respectively. The obtained compounds and their nanogels were evaluated as Topo-II inhibitors and DNA intercalators. The nanogel for compound 7 enhanced cytotoxicity in A549, HCT116, MCF-7, and HepG2 cancers by 35.93%, 34.29%, 50.91%, and 49.94% respectively. Moreover, the nanogel for compound 8 enhanced cytotoxicity in A549, HCT116, MCF-7, and HepG2 cancers by 31.13%, 34.09%, 49.59%, and 46.43% respectively. Furthermore, the nanogel for compound 9 enhanced cytotoxicity in A549, HCT116, MCF-7, and HepG2 cancers by 38.99%, 43.78%, 58.25%, and 57.73% respectively. Moreover, our derivatives 7, 7 (nanogel), 8, 8 (nanogel), 9 and 9 (nanogel) exhibited high selectivity against cancer cells and lower toxicity on VERO cells with IC

Indexed as

Antineoplastic AgentsIntercalating AgentsQuinoxalinesTopoisomerase II InhibitorsAnimalsCell Line, TumorCell ProliferationChlorocebus aethiopsDrug CarriersDrug DesignHep G2 CellsHumansMCF-7 CellsMolecular Docking SimulationVero CellsAntineoplastic AgentsDrug CarriersIntercalating AgentsQuinoxalinesTopoisomerase II InhibitorsAnticancer agentsDNA intercalatorsTopo-II inhibitors

Identifiers

PMID40214726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.